Price Reduction2 April 2026 at 09:55 am
Emcure Pharma Slashes Poviztra Starting Dose Price by 55% to Boost Patient Access
AI Summary
Emcure Pharmaceuticals Ltd. has announced a significant price reduction for its weight management drug, Poviztra® (semaglutide injection). The starting dose price of Poviztra® will now be available at Rs. 3,999/- per month, a 55% decrease. This price revision will make the innovator molecule more accessible to a larger patient base, addressing India's growing obesity epidemic. The innovator semaglutide molecule has been on the market for nearly a decade and is backed by robust clinical and real-world evidence.
Key Highlights
- Poviztra® starting dose price reduced by 55% to Rs. 3,999/- per month
- Prices of Poviztra® reduced by 47% on average across doses
- Emcure Pharma aims to expand access and enable more patients to benefit from this proven therapy at the revised price
- Semaglutide molecule is backed by nearly 50 clinical trials and has been taken by millions of patients worldwide
- Price reduction aims to address India's growing obesity epidemic
EMCUREPharmaceuticals
Emcure Pharmaceuticals LtdPrice Impact